. Author manuscript; available in PMC: 2022 Jun 1.

Published in final edited form as: J Invest Dermatol. 2020 Dec 30;141(6):1493–1502. doi: 10.1016/j.jid.2020.11.025

Table 1:

Trans-disease meta-analysis results for loci meeting criteria

Marker ID	Chr	Position (hg19)	Alleles (risk/non-risk)	Meta-analysis P-values			Meta-analysis Odds Ratios			Minor Allele Frequencies^a		Nearby Gene	BMI Locus?^b	New^c GWAS Locus?^b
Marker ID	Chr	Position (hg19)	Alleles (risk/non-risk)	P(Psoriasis)	P(T2D)	P(Both)	OR(Psoriasis)	OR(T2D)	OR(Both)	Psoriasis	T2D	Nearby Gene	BMI Locus?^b	New^c GWAS Locus?^b
rs840967	2	65701757	C/A	6.6x10⁻⁵	4.4x10⁻⁸	9.6x10⁻⁹	1.08	1.04	1.06	0.40	0.41	SPRED2	No	Psoriasis
rs12265333	10	102011211	A/G	1.6x10⁻⁶	7.1x10⁻⁷	1.0x10⁻⁹	1.12	1.04	1.08	0.49	0.49	CHUK	No	No
rs685870	11	64111928	T/C	8.5x10⁻⁹	7.8x10⁻⁵	1.0x10⁻¹¹	1.13	1.03	1.08	0.31	0.30	PRDX5	Yes^d	T2D
rs2292749	17	40818584	T/C	4.3x10⁻⁶	1.5x10⁻⁶	1.5x10⁻⁹	1.10	1.04	1.07	0.29	0.30	STAT3	No	No

Abbreviations are as follows: Chr, chromosome; OR, odds ratio; p, p-value; T2D, type 2 diabetes; BMI, body mass index; GWS, genome-wide significant (i.e. p<5x10⁻⁸).

Minor alleles are provided for each entire meta-analysis (cases and controls), rather than specigically for each disease.

We determine whether a locus is previously known to be associated with BMI, psoriasis, or T2D according to data from the GIANT and DIAGRAM consortium, as well as a search of the available literature.

To our knowledge, previously unreported.

The lead marker of the chromosome 11 locus (rs685870) is significantly associated with BMI in the GIANT consortium meta-analysis (2.3x10⁻⁹), but its effect (OR=1.01) is in the opposite direction to the signal we identified in our trans-disease meta-analysis (i.e. the risk allele is C rather than T), suggesting it is not in the same haplotype.